This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room.
Our connections and relationships within the oncology community give us the ability to innovate and deliver new medicines for patients. More than a decade ago, Novartis AG was the first company to form a dedicated global business unit for developing and launching innovative oncology medicines that address unmet treatment needs of patients. This early vision has led to one of the most dynamic portfolios of products in the marketplace.
Get the latest media and materials about our products: